VOYA Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-43,669
| Closed | -$1.76M | – | 2491 |
|
|
2026
Q1 | $1.76M | Buy |
43,669
+8
| +0% | +$172 | ﹤0.01% | 1241 |
|
|
2025
Q4 | $1.1M | Sell |
43,661
-129,273
| -75% | -$3.03M | ﹤0.01% | 1448 |
|
|
2025
Q3 | $3.91M | Buy |
172,934
+22,341
| +15% | +$521K | ﹤0.01% | 961 |
|
|
2025
Q2 | $2.61M | Buy |
150,593
+25,192
| +20% | +$466K | ﹤0.01% | 1188 |
|
|
2025
Q1 | $2.74M | Buy |
125,401
+2,250
| +2% | +$62.2K | ﹤0.01% | 1177 |
|
|
2024
Q4 | $3.93M | Buy |
123,151
+35,185
| +40% | +$1.06M | ﹤0.01% | 1057 |
|
|
2024
Q3 | $2.54M | Sell |
87,966
-35,650
| -29% | -$1.32M | ﹤0.01% | 1261 |
|
|
2024
Q2 | $4.74M | Sell |
123,616
-371,076
| -75% | -$16.8M | ﹤0.01% | 1023 |
|
|
2024
Q1 | $29.1M | Buy |
494,692
+238,159
| +93% | +$15.2M | 0.03% | 449 |
|
|
2023
Q4 | $15.4M | Buy |
256,533
+174,366
| +212% | +$8.85M | 0.02% | 601 |
|
|
2023
Q3 | $3.13M | Sell |
82,167
-139,247
| -63% | -$6.12M | ﹤0.01% | 1158 |
|
|
2023
Q2 | $20.2M | Sell |
221,414
-57,772
| -21% | -$4.98M | 0.02% | 514 |
|
|
2023
Q1 | $18.4M | Buy |
279,186
+113,880
| +69% | +$6.57M | 0.02% | 548 |
|
|
2022
Q4 | $8.55M | Sell |
165,306
-7,375
| -4% | -$391K | 0.01% | 771 |
|
|
2022
Q3 | $11.8M | Buy |
172,681
+52,109
| +43% | +$3.08M | 0.01% | 651 |
|
|
2022
Q2 | $5.45M | Buy |
120,572
+24,563
| +26% | +$1.12M | 0.01% | 707 |
|
|
2022
Q1 | $4.88M | Sell |
96,009
-7,867
| -8% | -$347K | 0.01% | 846 |
|
|
2021
Q4 | $4.91M | Buy |
103,876
+78,732
| +313% | +$3.1M | 0.01% | 848 |
|
|
2021
Q3 | $829K | Sell |
25,144
-337
| -1% | -$18.9K | ﹤0.01% | 1708 |
|
|
2021
Q2 | $1.61M | Sell |
25,481
-1,078
| -4% | -$55.6K | ﹤0.01% | 1319 |
|
|
2021
Q1 | $1.14M | Buy |
26,559
+181
| +0.7% | +$8.56K | ﹤0.01% | 1509 |
|
|
2020
Q4 | $1.51M | Buy |
26,378
+2,000
| +8% | +$84.6K | ﹤0.01% | 1281 |
|
|
2020
Q3 | $735K | Buy |
24,378
+3,521
| +17% | +$105K | ﹤0.01% | 1449 |
|
|
2020
Q2 | $681K | Sell |
20,857
-7,377
| -26% | -$237K | ﹤0.01% | 1457 |
|
|
2020
Q1 | $756K | Buy |
28,234
+4,247
| +18% | +$151K | ﹤0.01% | 1366 |
|
|
2019
Q4 | $734K | Buy |
23,987
+5,261
| +28% | +$146K | ﹤0.01% | 1643 |
|
|
2019
Q3 | $451K | Hold |
18,726
| – | – | ﹤0.01% | 1829 |
|
|
2019
Q2 | $475K | Buy |
18,726
+3,690
| +25% | +$75.1K | ﹤0.01% | 1819 |
|
|
2019
Q1 | $293K | Sell |
15,036
-684
| -4% | -$10.8K | ﹤0.01% | 2068 |
|
|
2018
Q4 | $207K | Buy |
15,720
+1,621
| +11% | +$24.9K | ﹤0.01% | 2207 |
|
|
2018
Q3 | $251K | Hold |
14,099
| – | – | ﹤0.01% | 2234 |
|
|
2018
Q2 | $310K | Buy |
+14,099
| New | +$324K | ﹤0.01% | 2126 |
|
Other funds holding APLS
VOYA Investment Management's APLS Position: Q2 2026 in Review
VOYA Investment Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 43,669 shares — an estimated $1.76M sold.
VOYA Investment Management first reported a position in APLS in Q2 2018 and held it in 32 quarters. The position peaked at $29.1M in Q1 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- VOYA Investment Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- VOYA Investment Management sold 43,669 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.76M.
- VOYA Investment Management first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 32 quarters.
- VOYA Investment Management's Apellis Pharmaceuticals position peaked at $29.1M in Q1 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.